This study reveals a potential antagonistic mechanism between CD20-targeted therapy and BTK inhibitors when used in combination for chronic lymphocytic leukemia, providing critical warnings and optimization directions for the design of future combination immunotherapies.
Literature Overview
The article titled "Efficacy of high‐frequency low‐dose rituximab and acalabrutinib in chronic lymphocytic leukemia," published in the journal HemaSphere, systematically investigates the efficacy and immune clearance mechanisms of high-frequency low-dose (HFLD) rituximab combined with acalabrutinib in treatment-naïve patients with chronic lymphocytic leukemia (CLL). Through intensive longitudinal sampling, the study reveals rapid but transient CLL cell clearance kinetics mediated by rituximab and, for the first time, reports that acalabrutinib significantly downregulates MS4A1 expression and CD20 levels, thereby weakening the antibody-dependent cellular phagocytosis (ADCP) effect—indicating a potential negative interaction. These findings challenge the current standard paradigm of combining BTK inhibitors (BTKi) with anti-CD20 monoclonal antibodies, suggesting a need to reevaluate the timing and sequence of combination strategies.Background Knowledge
Chronic lymphocytic leukemia (CLL) is an indolent B-cell malignancy characterized by the abnormal proliferation and accumulation of mature B lymphocytes in the peripheral blood, bone marrow, and lymphoid tissues. Although targeted therapies have significantly improved patient outcomes, most cases remain incurable, with issues of resistance and relapse persisting. Currently, CD20-targeted monoclonal antibodies such as rituximab, ofatumumab, and obinutuzumab are widely used in CLL treatment, with their primary clearance mechanism being antibody-dependent cellular phagocytosis (ADCP), mediated by liver Kupffer cells and splenic macrophages. However, clinical observations show that even at standard doses, these antibodies fail to completely eliminate circulating CLL cells, suggesting intrinsic resistance mechanisms. Known limiting factors include low CD20 expression on CLL cells, complement depletion, macrophage functional exhaustion (i.e., phagocytic fatigue), and CD20 antigen loss via trogocytosis. Additionally, B-cell receptor (BCR) signaling pathway inhibitors such as ibrutinib and acalabrutinib can promote the mobilization of CLL cells from lymphoid tissues into the peripheral blood by inhibiting BTK, theoretically enhancing mAb access to tumor burden. However, prior studies found that ibrutinib has off-target effects that suppress macrophage function, thereby weakening ADCP. The second-generation BTK inhibitor acalabrutinib has higher selectivity and does not exhibit similar suppression in vitro, making it a more ideal combination partner. This study was designed against this background, employing HFLD rituximab to overcome antigen modulation and maintain effector immune function, while evaluating its true effect in combination with acalabrutinib.
Research Methods and Experiments
The study enrolled 38 treatment-naïve patients with progressive CLL in a phase II clinical trial (NCT03788291). The treatment regimen involved HFLD rituximab alone during the first week: 50 mg intravenous infusion at 25 mg/h on Day 1; 50 mg subcutaneous injection on Day 3. Starting on Day 8, oral acalabrutinib (100 mg q12h) was added and continued for at least one year. Intensive longitudinal sampling (at time points shown in Figure 1) was used to monitor CLL cell counts, CD20 expression, complement activation, serum rituximab concentration, and ADCP function. Flow cytometry was used to quantify CD20 molecules on the surface of CLL cells (based on MESF standards), and scRNA-seq was employed to analyze transcriptional changes in MS4A1 (encoding CD20). In vitro ADCP assays involved co-culturing hMDMs from healthy donors with patient-derived CLL cells, with phagocytic index quantified using time-lapse video microscopy. All data were subjected to statistical analysis using non-parametric tests and mixed-effects models.Key Conclusions and Perspectives
Research Significance and Prospects
This study fundamentally challenges the widely held assumption that "BTKi + anti-CD20" represents an intensified regimen, revealing a potential mechanism by which acalabrutinib may antagonize rituximab efficacy through downregulation of MS4A1 expression. This finding has profound implications for drug development: future strategies should avoid simultaneous use of BTK inhibitors with mAbs dependent on ADCP, or explore alternative approaches such as intermittent or sequential dosing. Moreover, the HFLD regimen demonstrated rapid clearance capacity, suggesting its potential role in a "mobilize-clear" strategy—enhancing mAb efficacy when CLL cells are exposed in the periphery—warranting validation with other mAbs (e.g., obinutuzumab).
From a clinical monitoring perspective, CD20 expression dynamics during BTKi therapy should be routinely assessed to determine the optimal timing for mAb intervention. Additionally, with only one patient achieving uMRD complete remission, there is an urgent need to explore more effective combination regimens, such as incorporating the BCL2 inhibitor venetoclax. This study also offers new insights for disease modeling: developing humanized mouse models that simulate trogocytosis and ADCP exhaustion will aid in validating these mechanisms in vivo and screening next-generation mAbs.
Conclusion
This study systematically elucidates the mechanisms of high-frequency low-dose rituximab combined with acalabrutinib in chronic lymphocytic leukemia, revealing a complex interaction that appears synergistic but may actually involve antagonism. Although rituximab can efficiently clear circulating CLL cells in a short time, its effect is limited by the brief activity window of innate immune effectors. Moreover, while the addition of acalabrutinib promotes tumor cell mobilization, it unexpectedly downregulates MS4A1 and CD20 expression, weakening ADCP-mediated killing. This finding suggests that current mainstream combination immunotherapy strategies may not be optimal and could even be self-undermining due to target modulation. Future efforts should shift toward more precise sequential treatment designs—for example, using BTKi first to mobilize tumor cells to the periphery, followed by HFLD mAb for efficient clearance—thus maximizing the synergistic potential of each agent. Furthermore, developing novel anti-CD20 antibodies or bispecific molecules resistant to trogocytosis will be key to overcoming resistance. This study provides a mechanistic foundation for personalized immunotherapy in CLL, marking a pivotal shift from empirical combinations to mechanism-driven therapeutic strategies, with broad implications for the treatment paradigms of B-cell malignancies.
